Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Adipose tissue derived stromal cells for the treatment of neurological disorders

a stromal cell and adipose tissue technology, applied in the direction of fused cells, skeletal/connective tissue cells, peptide/protein ingredients, etc., can solve the problems of brain cell death, brain damage irreversible, high risk and discomfort of bone marrow stromal cells, etc., and achieve the effect of reducing the functional defici

Inactive Publication Date: 2009-09-01
VETSTEM BIOPHARMA INC
View PDF44 Cites 43 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the absence of treatment, these animals died because they failed to replenish their circulating blood cells; however, transplantation of bone marrow cells from syngeneic donor animals rescued the host animal.
However, extraction of bone marrow stromal cells presents a high level of risk and discomfort to the patient.
These injuries share the same common pathologic process of rapid cerebral edema leading to irreversible brain damage and eventually to brain cell death.
Stroke results in the destruction of brain tissue as a result of intracerebral hemorrhage or infarction.
Stroke may be caused by reduced blood flow or ischemia that results in deficient blood supply and death of tissues in one area of the brain (infarction).
The CNS tissue is highly dependent on blood supply and is very vulnerable to interruption of blood supply.
Even a brief interruption of the blood flow to the CNS can cause neurological deficit.
It has been observed that after blood flow is restored to areas of the brain that have suffered an ischemic injury, secondary hemodynamic disturbances have long lasting effects that interfere with the ability of the blood to supply oxygen to CNS tissues.
Similarly, interruption of the blood flow to the spinal cord, for even short periods of time, can result in paralysis.
Results of various trials have yielded disappointing efficacy data and some evidence of safety problems, including increased mortality or psychotic effects which resulted in the early termination of the trials.
Existing therapies rely on prompt treatment (i.e within minutes / hours) following a stroke but there is presently no effective or beneficial therapy that can be applied at later time points (days / weeks) after the onset of stroke.
Thus there remains a large unmet need for treatments that improve neurological function after the onset of stroke.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adipose tissue derived stromal cells for the treatment of neurological disorders
  • Adipose tissue derived stromal cells for the treatment of neurological disorders
  • Adipose tissue derived stromal cells for the treatment of neurological disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Hematopoietic Commitment by Adipose Tissue-Derived Stromal Cells

[0133]A. Stromal cells are isolated from human adipose tissue according to the methods described in U.S. patent application Ser. No. 09 / 240,029, Filed Jan. 29, 1999, now U.S. Pat. No. 6,153,432 (the contents of which are incorporated by reference), and using the modifications to the growth medium as described above. Briefly, human preadipocytes were isolated from adipose tissue removed by liposuction surgery according to the procedures previously described by Rodbell and Hauner (Rodbell (1967) and (1974); Hauner, supra). Preadipocytes from the stromal-vascular fraction were resuspended in DMEM (high glucose) media containing 10% fetal bovine serum, 5% chick embryo extract, and antibiotics and plated at 25,000 cells / well in each of the wells of a 96 well plate (150 μl / well). The cells were then placed in a 37° C. 5% CO2 incubator and allowed to settle overnight. The cells are cultured as primary cultures for a period of ...

example 2

Astroglial Commitment by Human Adipose Tissue-Derived Stromal Cells

[0137]A. Stromal cells are isolated from human adipose tissue according to the methods described above. The cells are cultured as primary cultures for a period of up to 5 days following initial plating in a medium composed of, but not limited to, DMEM (high glucose) media containing 10% fetal bovine serum, 5% chick embryo extract, and antibiotics at 37° C. Cells are harvested by trypsin / EDTA digestion prior to differentiation / implantation.

[0138]Cells are transplanted into the central nervous system of immunodeficient mice or rats. Nude / beige or SCID mice or nude rats are anesthetized in a sealed chamber using 3% halothane in oxygen; anesthesia is maintained by intramuscular injection of 6 mg / kg of xylozine and 60 mg / kg of ketamine. The animals are transferred to a sterotaxic apparatus in a clean field. A 2-to-5-mm incision is made in the scalp 2 mm lateral to the bregma. A burr hole is made in the bone 3 mm lateral t...

example 3

Neuronal Commitment by Human Adipose Tissue-Derived Stromal Cells

[0141]Improved Repair and Functional Recovery in a Traumatic Nervous System Injury

[0142]Stromal cells are isolated from human adipose tissue of an individual patient for autologous or allogeneic transplantation to a histocompatible recipient according to the methods described above. The cells are cultured as primary cultures for a period of up to 5 days following initial plating in a medium composed of, but not limited to, DMEM (high glucose) media with 1 mM glutamine but without pyruvate, containing 10% fetal bovine serum, 10% newborn calf serum, nucleoside stocks, 0.1 mM 2-mercaptoethanol, 1000 units / ml of leukemia inhibitory factor and antibiotics at 37° C.

[0143]Cells are harvested by trypsin / EDTA digestion prior to differentiation / implantation. Cells are then plated on tissue culture plastic substrate coated with 0.1% sterile gelatin solution. Cells are harvested during rapid growth stage by 0.25% trypsin and 1 mM ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
temperaturesaaaaaaaaaa
temperaturesaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a treatment of neural injury and neurodegenerative diseases. Also included in the present invention is the use of adipose tissue derived stromal cells for the treatment of neural injury (stroke, traumatic brain injury, spinal cord injury) and neurodegeneration (i.e. Parkinson's disease).

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application is a continuation-in-part of U.S. patent application Ser. No. 09 / 793,173, filed on Feb. 26, 2001, which claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60 / 185,338, filed Feb. 26, 2000, all of which are herein incorporated by reference in their entirety.BACKGROUND OF THE INVENTION[0002]A stem cell must meet the following criteria: (1) ability of a clonal stem cell population to self-renew; (2) ability of a clonal stem cell population to generate a new, terminally differentiated cell type in vitro; (3) ability of a clonal stem cell population to replace an absent terminally differentiated cell population when transplanted into an animal depleted of its own natural cells.[0003]The neonatal period in human development is characterized by the presence of “stem” cells with the potential to develop along multiple differentiation pathways. The terminal differentiation of these cells is deter...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A01N63/00C12N5/00C12N5/06C12N5/08C12N5/16A61K35/35C12N5/074C12N5/0775
CPCC12N5/0607A61K35/35C12N5/0667A61K38/00A61P25/00
Inventor WILKISON, WILLIAM O.GIMBLE, JEFFREY M.VANGURI, PADMAVATHY
Owner VETSTEM BIOPHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com